Incyte Acquires Vega In Hematology-Focused Diversification Plan
The company will pay $1.25bn up front to acquire a protein S modulator in Phase III for von Willebrand disease.
Scrip - June 8, 2026

People On The Move: Appointments At Bayer Consumer Health, ANEFP, IADSA
A round-up of the latest people news: Bayer Consumer Health makes leadership appointments; ANEFP names president; IADSA elects chair; PGEU appoints 2027 president.
HBW Insight - June 8, 2026

OTC Industry Warned: Don’t Lose Sight Of Community Pharmacy
AESGP Annual Meeting: Community pharmacy risks being overlooked as manufacturers chase online growth, despite evidence it remains the industry's most powerful conversion channel and an untapped source of long-term revenue.
HBW Insight - June 8, 2026

Pipeline Watch: ASCO 2026 Steals The Readout Spotlight
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 8, 2026

Deals Shaping The Medtech And Diagnostics Industries, May 2026
An interactive look at medtech and diagnostics deals made during May 2026. Data courtesy of Biomedtracker.
Medtech Insight - June 8, 2026

Dexcom G7 Adds Five Hours Of Daily Time In Range Over Standard Care, Trial Shows
A 26-week randomized trial in non-insulin type 2 patients has handed Dexcom its most consequential clinical result yet — Level A evidence that continuous glucose monitoring meaningfully outperforms standard care in a population that guidelines have largely left behind.
Medtech Insight - June 8, 2026

Krka Aspires For Top Five Generics Position In All Traditional Markets
As the Slovenian pharma giant continues to scale its products with an evidently strong revenue growth, it hopes to prove that consistency equals European market success.
Generics Bulletin - June 8, 2026

ADA 2026: Structure Therapeutics’ Aleniglipron Shows Improved Tolerability, But Competition Looms
Tolerability concerns that have dogged Structure Therapeutics’ aleniglipron eased with new data, but an AstraZeneca readout could set up the next test for the oral GLP-1.
Scrip - June 8, 2026

India Gains Biologics Muscle As Aurobindo Opens TheraNym
Aurobindo’s TheraNym launch gives India a rare integrated biologics CMO platform, anchored by MSD, with 120,000 liters of planned capacity and ambitions to compete in global supply chains by 2030.
Generics Bulletin - June 8, 2026

Alvotech Refiles Golimumab and Aflibercept In US
Alvotech has now resubmitted filings to the US FDA for its biosimilar rivals to Simponi/Simponi Aria (golimumab) and Eylea (aflibercept), after working to resolve compliance issues relating to its Reykjavik manufacturing facility.
Generics Bulletin - June 8, 2026

Industry Urges Dedicated Support For Europe’s €13B IVD Sector
Position paper on IVDR revision welcomes many of the EU’s proposed changes, but requests tweaks to orphan diagnostics, risk classifications and health institution tests.
Medtech Insight - June 8, 2026

ADA 2026: Lilly Sees Retatrutide Helping Many Patients, Not Just Most Obese
The triple-G agonist should help Eli Lilly carve out a new segment in the high BMI obesity market, but its low dose may also compete with established rivals.
Scrip - June 8, 2026

Podcast: GATC Health’s Derisq AI, A FICO Score For Drug Development
In this episode of the In Vivo podcast, GATC Health's Tyrone Lam discusses Derisq AI, the techbio's simulation platform, as a neutral “Switzerland” for drugs, de?risking trials, insurance underwriting and pharma–biotech deal decisions.
In Vivo - June 8, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Revolution’s daraxonrasib makes splash at ASCO; Merck & Co. lays out oncology vision; US legislators bristle over US-China deals; obesity challengers at ADA; and big pharma CEO pay rebounds in 2025.
Scrip - June 8, 2026